Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Issues $800M of Senior Notes

NEW YORK (GenomeWeb) – Thermo Fisher Scientific issued $800 million in aggregate principal amount of 3.3 percent senior notes due in 2022, the company said in a document filed with the US Securities and Exchange Commission on Friday after the close of the market. 

The company announced its plans to offer the dollar-denominated notes and then priced them earlier this month. The company will use net proceeds principally to pay back debt, including the $400 million aggregate principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20, it said. The company has also filed a registration document with the SEC for a euro-denominated offering of its senior notes due in 2025. 

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.